In this review, useful biopsies were defined as those that definitively established the diagnosis and which provided solid guidance to the attending nephrologist on how to treat the patient. Of the 196 kidney biopsies done between 2000 and 2008 for which complete data were available, we determined that 172 (88%) were useful as defined above. In particular, of the 113 kidney biopsies that were done for diagnostic purposes (types 1, 2, 3) 85% were helpful, and all of the procedures done to assess severity were also deemed helpful. From a clinical perspective, categories 1–4 were all considered useful and could have been combined into one group. We divided them into four distinct subcategories to better characterize how nephrologists utilize the information content of a kidney biopsy in a productive manner.
In most circumstances, a renal biopsy is a semi-elective procedure, and technical failures can occur when the procedure fails to obtain adequate tissue. Of all the biopsies analyzed in this study, only 3 were technical failures. The fact that renal biopsies were not useful in 12.2% of cases needs to be considered in assessing the benefit of performing biopsies. In those cases, further testing is needed after the biopsy, and treatment has to be guided by clinical factors rather than the histopathological findings. In our study, we found the overall yield of uninformative biopsies was 12.2%, which is below the 20% threshold that we defined as an acceptable rate. This constitutes an acceptable risk/benefit ratio. Despite the potential risks involved, families can be reassured that a renal biopsy will be helpful in the great majority of patients who must undergo the procedure.
In judging this study, it is worth noting that there has been general uniformity in practice and staffing over the study period. One physician (HT) has been one of the primary nephrologists over the past 20 years and active throughout the 8-year study period and one pathologist (EV) interpreted all the biopsies from 2000 to 2007. It is reasonable to conclude that there was consistency in the use of kidney biopsies to predict, diagnose, and treat patients suspected of having kidney disease. The number of biopsies performed per year (Figure 1) showed no consistent trend, upward or downward, reinforcing the uniformity of the practice. We chose to focus on the years 2000–2008 in order to shed light on the utility of the kidney biopsy during a period that reflects current medical practice. Although it would have been optimal to have the interpretation of all biopsy reports reviewed by the independent observer, the four primary authors agreed in over 80% of cases. Moreover, the physician who performed the kidney biopsy was never involved in the retrospective assessment of diagnostic utility of the procedure. Despite the focused duration of the study and the single center nature of the review, a sufficient number of patients were identified that enabled conclusions to be drawn from our experience.
It is important to acknowledge that the study cannot definitively assess the utility of kidney biopsies performed to determine severity (type 4) in SLE patients. We assumed the results to be useful, excluding those in which a technical failure occurred, because the biopsies identified the WHO class of the disease in all cases and presumably guided treatment by the rheumatologists. This reflects the approach to patient management at Schneider Children's Hospital in which the care of children with SLE nephritis is delivered primarily by the rheumatologists unless the patients have specific issues such as hypertension, edema, or progress to end stage kidney disease. The utility of the biopsy may vary in those centers where nephrologists directly supervise the full care of patients with SLE. In addition, this study was limited to native kidney biopsies and did not address the value of transplant biopsies. Finally, we have not commented on complications of the procedure because we have reviewed our experience in a previous publication which confirms the overall safety of kidney biopsies performed using ultrasound localization [14].
Based upon clinical experience and perennial difficulties distinguishing between FSGS and MCNS clinically, we anticipated that kidney biopsies performed on these patients would have the highest non-diagnostic rate. Table 2 indicates, however, that the rate of unhelpful biopsies performed on FSGS and MCNS patients was not significantly different compared to biopsies performed for other conditions, and the maximum non-diagnostic rates for any of the major diseases was 10–20%. The entities with higher failure rates involved small numbers of patients, which precludes meaningful conclusions.
It is likely that nephrologists will always have to grapple with the fact that there will be a percentage of biopsies that fail to yield a diagnosis. Too small a percentage suggests too stringent requirements for performing a kidney biopsy. Conversely, a high percentage suggests that kidney biopsies are being performed for inadequate indications. The issue of an acceptable value will vary depending upon the urgency of the patient's clinical situation, the spectrum of clinical outcomes that might occur, and the availability of treatments that can materially alter the outcome of an anticipated disease entity. For example, pediatric surgeons recognize that not every child with abdominal pain who undergoes a laparotomy should have appendicitis because they realize it is better to occasionally find a normal abdomen rather than manage a ruptured appendix. Interestingly, a recent report in the surgical literature suggests that an acceptable negative appendectomy rate is 10–20%, in the range of our rate of negative kidney biopsies [15]. In view of the spectrum of kidney problems that mandated a biopsy, it may be difficult to define a single acceptable rate of non-diagnostic biopsies, and we offer our findings as a basis for future considerations on this issue.
In summary, we present our findings about the diagnostic value of a kidney biopsy in a varied group of pediatric patients. The overall rate of 12% seems to strike an appropriate balance between maximizing the application and minimizing the risk of this invasive procedure. Our findings may need to be reassessed as clinical information regarding specific disease changes and technical innovations are introduced in the performance of kidney biopsies and handling renal tissue specimens.